Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha Inhibitors

Detalhes bibliográficos
Autor(a) principal: Andrade, Filipa
Data de Publicação: 2018
Outros Autores: Ferreira, Sandra, Torres, Tiago
Tipo de documento: Artigo
Idioma: por
Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Texto Completo: https://doi.org/10.29021/spdv.75.3.813
Resumo: Psoriasis is a chronic inflammatory disease that affects 2 to 3% of the population. Several studies have shown that psoriasis is associated with an increased risk of cardiovascular disease due to the increased prevalence of traditional cardiovascular risk factors, and chronic systemic inflammation that promotes the development of endothelial dysfunction and premature atherosclerosis. This literature review aims to evaluate the impact of tumor necrosis factor inhibitors in endothelial function and the risk of cardiovascular disease in patients with moderate to severe psoriasis. The studies conducted to date suggest that treatment of psoriasis with these drugs is associated with improvement in endothelial dysfunction markers and subclinical atherosclerosis and a decreased risk of cardiovascular disease.
id RCAP_69d11f32cdc5c2c2b5b92c93fb4800be
oai_identifier_str oai:ojs.revista.spdv.com.pt:article/813
network_acronym_str RCAP
network_name_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository_id_str 7160
spelling Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha InhibitorsPsoríase e Doença Cardiovascular: Impacto da Terapêutica com Inibidores do TNF-alfaAtherosclerosisCardiovascular Diseases/chemically inducedEndotheliumVascular/drug effectsPsoriasis/drug therapyTumor Necrosis Factor-alpha/antagonists & inhibitorsAteroscleroseDoença Cardiovascular/induzida quimicamenteEndotélio Vascular/efeitos de medicamentosFactor de Necrose Tumoral alfa/antagonistas & inibidoresPsoríase/tratamentoPsoriasis is a chronic inflammatory disease that affects 2 to 3% of the population. Several studies have shown that psoriasis is associated with an increased risk of cardiovascular disease due to the increased prevalence of traditional cardiovascular risk factors, and chronic systemic inflammation that promotes the development of endothelial dysfunction and premature atherosclerosis. This literature review aims to evaluate the impact of tumor necrosis factor inhibitors in endothelial function and the risk of cardiovascular disease in patients with moderate to severe psoriasis. The studies conducted to date suggest that treatment of psoriasis with these drugs is associated with improvement in endothelial dysfunction markers and subclinical atherosclerosis and a decreased risk of cardiovascular disease.A psoríase é uma doença inflamatória crónica que atinge 2 a 3% da população. Vários estudos têm demonstrado que a psoríase se associa a um aumento de risco de doença cardiovascular devido ao aumento da prevalência de fatores de risco cardiovasculares tradicionais, e à inflamação sistémica crónica que promove o desenvolvimento de disfunção endotelial e aterosclerose prematura. Esta revisão da literatura tem como objetivo avaliar o impacto dos inibidores do fator de necrose tumoral alfa na função endotelial e no risco de doença cardiovascular nos doentes com psoríase moderada a grave. Os estudos realizados até ao momento sugerem que o tratamento da psoríase com estes fármacos se associa a melhoria dos marcadores de disfunção endotelial e aterosclerose subclínica e a diminuição do risco de doença cardiovascular.Sociedade Portuguesa de Dermatologia e Venereologia2018-01-22T00:00:00Zjournal articleinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://doi.org/10.29021/spdv.75.3.813oai:ojs.revista.spdv.com.pt:article/813Journal of the Portuguese Society of Dermatology and Venereology; Vol 75 No 3 (2017): Julho - Setembro; 251-258Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 75 n. 3 (2017): Julho - Setembro; 251-2582182-24092182-2395reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revista.spdv.com.pt/index.php/spdv/article/view/813https://doi.org/10.29021/spdv.75.3.813https://revista.spdv.com.pt/index.php/spdv/article/view/813/508Andrade, FilipaFerreira, SandraTorres, Tiagoinfo:eu-repo/semantics/openAccess2022-10-06T12:35:04Zoai:ojs.revista.spdv.com.pt:article/813Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T16:11:03.647931Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse
dc.title.none.fl_str_mv Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha Inhibitors
Psoríase e Doença Cardiovascular: Impacto da Terapêutica com Inibidores do TNF-alfa
title Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha Inhibitors
spellingShingle Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha Inhibitors
Andrade, Filipa
Atherosclerosis
Cardiovascular Diseases/chemically induced
Endothelium
Vascular/drug effects
Psoriasis/drug therapy
Tumor Necrosis Factor-alpha/antagonists & inhibitors
Aterosclerose
Doença Cardiovascular/induzida quimicamente
Endotélio Vascular/efeitos de medicamentos
Factor de Necrose Tumoral alfa/antagonistas & inibidores
Psoríase/tratamento
title_short Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha Inhibitors
title_full Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha Inhibitors
title_fullStr Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha Inhibitors
title_full_unstemmed Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha Inhibitors
title_sort Psoriasis and Cardiovascular Disease: Impact of Therapy with TNF-alpha Inhibitors
author Andrade, Filipa
author_facet Andrade, Filipa
Ferreira, Sandra
Torres, Tiago
author_role author
author2 Ferreira, Sandra
Torres, Tiago
author2_role author
author
dc.contributor.author.fl_str_mv Andrade, Filipa
Ferreira, Sandra
Torres, Tiago
dc.subject.por.fl_str_mv Atherosclerosis
Cardiovascular Diseases/chemically induced
Endothelium
Vascular/drug effects
Psoriasis/drug therapy
Tumor Necrosis Factor-alpha/antagonists & inhibitors
Aterosclerose
Doença Cardiovascular/induzida quimicamente
Endotélio Vascular/efeitos de medicamentos
Factor de Necrose Tumoral alfa/antagonistas & inibidores
Psoríase/tratamento
topic Atherosclerosis
Cardiovascular Diseases/chemically induced
Endothelium
Vascular/drug effects
Psoriasis/drug therapy
Tumor Necrosis Factor-alpha/antagonists & inhibitors
Aterosclerose
Doença Cardiovascular/induzida quimicamente
Endotélio Vascular/efeitos de medicamentos
Factor de Necrose Tumoral alfa/antagonistas & inibidores
Psoríase/tratamento
description Psoriasis is a chronic inflammatory disease that affects 2 to 3% of the population. Several studies have shown that psoriasis is associated with an increased risk of cardiovascular disease due to the increased prevalence of traditional cardiovascular risk factors, and chronic systemic inflammation that promotes the development of endothelial dysfunction and premature atherosclerosis. This literature review aims to evaluate the impact of tumor necrosis factor inhibitors in endothelial function and the risk of cardiovascular disease in patients with moderate to severe psoriasis. The studies conducted to date suggest that treatment of psoriasis with these drugs is associated with improvement in endothelial dysfunction markers and subclinical atherosclerosis and a decreased risk of cardiovascular disease.
publishDate 2018
dc.date.none.fl_str_mv 2018-01-22T00:00:00Z
dc.type.driver.fl_str_mv journal article
info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://doi.org/10.29021/spdv.75.3.813
oai:ojs.revista.spdv.com.pt:article/813
url https://doi.org/10.29021/spdv.75.3.813
identifier_str_mv oai:ojs.revista.spdv.com.pt:article/813
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv https://revista.spdv.com.pt/index.php/spdv/article/view/813
https://doi.org/10.29021/spdv.75.3.813
https://revista.spdv.com.pt/index.php/spdv/article/view/813/508
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Sociedade Portuguesa de Dermatologia e Venereologia
publisher.none.fl_str_mv Sociedade Portuguesa de Dermatologia e Venereologia
dc.source.none.fl_str_mv Journal of the Portuguese Society of Dermatology and Venereology; Vol 75 No 3 (2017): Julho - Setembro; 251-258
Revista da Sociedade Portuguesa de Dermatologia e Venereologia; v. 75 n. 3 (2017): Julho - Setembro; 251-258
2182-2409
2182-2395
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron:RCAAP
instname_str Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
instacron_str RCAAP
institution RCAAP
reponame_str Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
collection Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
repository.name.fl_str_mv Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação
repository.mail.fl_str_mv
_version_ 1799130566709215232

Registros relacionados